Research letterGuselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review
References (3)
- et al.
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
J Am Acad Dermatol
(2011)
There are more references available in the full text version of this article.
Cited by (0)
Funding sources: None.
Conflicts of interest: Dr Rosmarin consulted or served on the speakers' bureau for Abbvie, Dermavant, Lilly, Novartis, Janssen, Regeneron, Sanofi, Pfizer, and Celgene. All other authors have no conflicts of interest to disclose.
© 2018 by the American Academy of Dermatology, Inc.